KCT0002713已完成未知
efficacy and safety of Aralia elata seem. extract powder in the evaluation of on blood pressure improving : 12 weeks, randomized, double-blind, placebo-controlled clinical trial
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 65(Year)（—）
- 性别
- All
入选标准
- •1) Male and female subject aged between 19 years and 65 years.
- •2) subjects who without a medical history of high blood pressure in within the last 3 months and SBP 120~149mmHg or DBP 85~94mmHg
- •3) subjects who decided to voluntarily participate in this clinical trial and complete to sign on the informed consent
排除标准
- •1) subjects who more than SBP 150mmHg or DBP 95mmHg
- •2) subjects who correspond to high risk group about cerebrovascular and cardiovascular disease incidence risk (more than ASCVD risk 15%)
- •3) subjects who intake antihypertensive agent within the last 3 months
- •4) subject who get diagnosed secondary hypertension
- •5) subject who get surgery of coronary arterioplasty, coronary artery bypass graft through transdermal to treat for cerebrovascular and cardiovascular disease within the last 6 months.
- •6) subjects who have acute severe cerebrovascular and cardiovascular disease such as heart failure, myocardial infarction, stroke.
- •7) subjects who have renal disease such as acute chronic renal failure and nephrotic syndrome
- •8) subjects who have acute/chronic inflammatory such as cancer, rheumatic disease, autoimmune disease, gastrointestinal disease
- •10) subjects who have hypersensitivity with drug or funtional foods
- •11) subject who get a medical history of psychopharmacotherapy with in last 2 months before screening test
- •12) subject who are dependent on drugs or alcohol
- •13) subject who participated in any clinical trial within 2 months before screening test
- •14) subject who show the following results at the test
- •(AST, ALT )
- •15) subjects who are pregnant and breastfeeding female
- •16) subject who do not perform adequate contraception in the urban eligible women (except woman who undergo sterilization operation)
- •17) subject who deemed inappropriate to participate this clinical trial by research director due to other reasons including screening test
研究者
相似试验
进行中（未招募）
不适用
EFFICACY AND SAFETY OF ERAXIS?/ECALTA (ANIDULAFUNGIN) COMPARED TO CANCIDAS (CASPOFUNGIN) IN NEUTROPENIC PATIENTS WITH INVASIVE CANDIDA INFECTION - NDInvasive candida infectionsMedDRA version: 9.1Level: LLTClassification code 10064954Term: Invasive candidiasisEUCTR2008-005277-35-ITPFIZER70
已完成
2 期
Clinical efficacy and safety of the ealry intervention with Tolvaptan(V2 receptorinhibiter)in hospitalized patients with acute exacerbation of chronic heart failur:A randomized open-labeled parallel controlled studyJPRN-UMIN000012716JI-TOKUSHUKAI MEDICAL CENTER Cardiovascular Medicine100
招募中
2 期
Safety and efficacy assessment of Alexandrite laser device in hair reductiounwanted hair.IRCT20190210042676N15Parnian Gostar Parto Sanj30
招募中
不适用
Evaluation of the effectiveness of ALA for an improvement of exercise tolerability in patients with COPD: pilot studyJPRN-UMIN000023179Juntendo University, Faculty of Medicine12
进行中（未招募）
不适用
EFFICACY AND SAFETY OF ERAXIS™/ECALTA® (ANIDULAFUNGIN) COMPARED TO CANCIDAS® (CASPOFUNGIN) IN PATIENTS WITH CANDIDA DEEP TISSUE INFECTIOEUCTR2008-005278-11-PTPfizer Inc, 235 East 42nd Street, New York, NY 1001760